Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Bumped Up to Buy by Wall Street Zen

Wall Street Zen upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

A number of other research firms have also recently commented on MDGL. Canaccord Genuity Group lifted their price objective on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research report on Wednesday. Wells Fargo & Company began coverage on shares of Madrigal Pharmaceuticals in a report on Monday, July 27th. They issued an “overweight” rating and a $685.00 target price on the stock. Wolfe Research raised shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target on the stock in a research note on Tuesday, August 4th. UBS Group reaffirmed a “buy” rating and set a $735.00 price target on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 14th. Finally, Citigroup lifted their price target on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $706.87.

Madrigal Pharmaceuticals Price Performance

Shares of MDGL opened at $399.63 on Friday. The firm has a market capitalization of $9.28 billion, a PE ratio of -66.83 and a beta of -0.98. The stock’s 50 day moving average is $486.74 and its two-hundred day moving average is $497.41. Madrigal Pharmaceuticals has a twelve month low of $353.54 and a twelve month high of $615.00. The company has a current ratio of 3.05, a quick ratio of 2.94 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping the consensus estimate of ($1.09) by $2.92. The business had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same quarter in the previous year, the company earned ($5.08) EPS. Research analysts anticipate that Madrigal Pharmaceuticals will post -2.08 earnings per share for the current year.

Insider Activity at Madrigal Pharmaceuticals

In other news, Director Bros. Advisors Lp Baker purchased 76,140 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were purchased at an average price of $384.32 per share, with a total value of $29,262,124.80. Following the purchase, the director directly owned 2,040,682 shares of the company’s stock, valued at approximately $784,274,906.24. This represents a 3.88% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Shannon T. Kelley sold 1,077 shares of the business’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $400.00, for a total value of $430,800.00. Following the completion of the transaction, the general counsel owned 10,397 shares in the company, valued at approximately $4,158,800. This trade represents a 9.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,324 shares of company stock worth $7,011,982. Corporate insiders own 17.60% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Jupiter Topco LLC purchased a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at $1,039,650,000. Paulson & CO. Inc. purchased a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $719,524,000. BlackRock Inc. purchased a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth about $644,753,000. Janus Henderson Group PLC lifted its position in shares of Madrigal Pharmaceuticals by 27.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock worth $1,051,727,000 after purchasing an additional 433,804 shares during the period. Finally, William Blair Investment Management LLC bought a new stake in shares of Madrigal Pharmaceuticals during the 2nd quarter valued at about $174,038,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals News Roundup

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.